CRP and interstitial lung disease: TCZ was administered in a phase 2 study (FaSScinate), and the data suggested this drug played a role in the IL-6 pathway in SSc-ILD and treatment of early SSc with elevated C-Reactive protein (CRP) and that it led to the stabilization of the FVC% in the tocilizumab group vs. a clinically meaningful decline in the placebo group over 48 weeks [48].